Lunit, a Korean developer of AI-powered cancer diagnostics and therapeutics, has partnered with the U.S. National Cancer Institute’s Center for Cancer Research, part of the National Institutes of Health (NIH), to integrate its AI biomarker platforms into the institute’s clinical research programs.
Lunit will apply its AI biomarker tools to NCI cancer trials to support personalized treatment development.
Under the agreement, Lunit’s image analysis tools—SCOPE IO and SCOPE universal IHC—will be used to analyze whole-slide pathology images from NCI trials.
The goal is to generate data on the tumor microenvironment and immune phenotypes to support the development of personalized cancer treatments and improve immunotherapy response predictions.
Lunit said the two organizations plan to jointly publish findings and present at international conferences. The partnership builds on Lunit’s earlier collaboration with the Society for Immunotherapy of Cancer and marks another move to expand the role of AI in oncology research.